KR20000075642A - 세로토닌-2 수용체 길항작용 및 알파 1-저해 작용을 갖는 피롤로티아진 및 피롤로티아제핀 화합물 - Google Patents

세로토닌-2 수용체 길항작용 및 알파 1-저해 작용을 갖는 피롤로티아진 및 피롤로티아제핀 화합물 Download PDF

Info

Publication number
KR20000075642A
KR20000075642A KR1019997007707A KR19997007707A KR20000075642A KR 20000075642 A KR20000075642 A KR 20000075642A KR 1019997007707 A KR1019997007707 A KR 1019997007707A KR 19997007707 A KR19997007707 A KR 19997007707A KR 20000075642 A KR20000075642 A KR 20000075642A
Authority
KR
South Korea
Prior art keywords
group
following formula
compound
compound represented
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1019997007707A
Other languages
English (en)
Korean (ko)
Inventor
미즈노아키라
시바타마코토
가메이도모에
후카미하루카즈
이노마타노리오
Original Assignee
도리이 신이치로
산토리 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 도리이 신이치로, 산토리 가부시키가이샤 filed Critical 도리이 신이치로
Publication of KR20000075642A publication Critical patent/KR20000075642A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1019997007707A 1997-12-26 1998-12-25 세로토닌-2 수용체 길항작용 및 알파 1-저해 작용을 갖는 피롤로티아진 및 피롤로티아제핀 화합물 Ceased KR20000075642A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP1997-366757 1997-12-26
JP9366757A JPH11193290A (ja) 1997-12-26 1997-12-26 ピロールスルホンアミド系化合物

Publications (1)

Publication Number Publication Date
KR20000075642A true KR20000075642A (ko) 2000-12-26

Family

ID=18487596

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019997007707A Ceased KR20000075642A (ko) 1997-12-26 1998-12-25 세로토닌-2 수용체 길항작용 및 알파 1-저해 작용을 갖는 피롤로티아진 및 피롤로티아제핀 화합물

Country Status (9)

Country Link
US (3) US6331623B1 (enExample)
EP (1) EP0970089A2 (enExample)
JP (1) JPH11193290A (enExample)
KR (1) KR20000075642A (enExample)
CN (2) CN1131870C (enExample)
AU (1) AU752510B2 (enExample)
CA (1) CA2282815A1 (enExample)
HU (1) HUP0001183A3 (enExample)
WO (1) WO1999033841A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11193289A (ja) * 1997-12-26 1999-07-21 Suntory Ltd ピロールスルホンアミド誘導体
JPH11193290A (ja) * 1997-12-26 1999-07-21 Suntory Ltd ピロールスルホンアミド系化合物
EP4092013A1 (en) 2017-06-20 2022-11-23 Imbria Pharmaceuticals, Inc. Compositions and methods for increasing efficiency of cardiac metabolism
US12318382B2 (en) 2018-10-17 2025-06-03 Imbria Pharmaceuticals, Inc. Methods of treating rheumatic diseases using trimetazidine-based compounds
EP3976101A4 (en) 2019-05-31 2023-06-21 Imbria Pharmaceuticals, Inc. FIBROSIS TREATMENT METHODS USING COMPOUNDS THAT PROMOTE GLUCOSE OXIDATION
US11530184B2 (en) 2020-06-30 2022-12-20 Imbria Pharmaceuticals, Inc. Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11780811B2 (en) 2020-06-30 2023-10-10 Imbria Pharmaceuticals, Inc. Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11883396B2 (en) 2021-05-03 2024-01-30 Imbria Pharmaceuticals, Inc. Methods of treating kidney conditions using modified forms of trimetazidine

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3198117B2 (ja) 1990-02-07 2001-08-13 サントリー株式会社 ピロロアゼピン誘導体
FR2675802B1 (fr) * 1991-04-26 1993-12-24 Rhone Poulenc Rorer Sa Antiserotonines, leur preparation et les medicaments les contenant.
ATE236163T1 (de) 1991-08-07 2003-04-15 Suntory Ltd Pyrroloazepinverbindungen
AU655841B2 (en) * 1991-08-07 1995-01-12 Daiichi Suntory Pharma Co., Ltd Pyrroloazepine derivative
ATE246682T1 (de) * 1993-12-24 2003-08-15 Daiichi Suntory Pharma Co Ltd Benzothiazinderivate
DE69630184T2 (de) 1995-11-02 2004-08-12 Daiichi Suntory Pharma Co., Ltd. Verfahren zur Herstellung von 1-substituierten Pyrrol-3-carbonsäure-Derivaten
ES2179218T3 (es) 1995-12-01 2003-01-16 Suntory Ltd Derivados de pirroloacepina.
JPH10251258A (ja) 1997-03-14 1998-09-22 Suntory Ltd ピロロアゼピン系化合物
JPH11193289A (ja) 1997-12-26 1999-07-21 Suntory Ltd ピロールスルホンアミド誘導体
JPH11193290A (ja) * 1997-12-26 1999-07-21 Suntory Ltd ピロールスルホンアミド系化合物
ES2220396T3 (es) 1999-02-17 2004-12-16 Daiichi Suntory Pharma Co., Ltd. Farmacos terapeuticos para la claudicacion intermitente que comprenden pirroloazepinas.

Also Published As

Publication number Publication date
US20020137928A1 (en) 2002-09-26
JPH11193290A (ja) 1999-07-21
EP0970089A2 (en) 2000-01-12
CN1495163A (zh) 2004-05-12
CA2282815A1 (en) 1999-07-08
CN1131870C (zh) 2003-12-24
US20030229070A1 (en) 2003-12-11
HUP0001183A2 (hu) 2000-10-28
US6583296B2 (en) 2003-06-24
US6331623B1 (en) 2001-12-18
US6743913B2 (en) 2004-06-01
CN1193014C (zh) 2005-03-16
AU752510B2 (en) 2002-09-19
WO1999033841A2 (en) 1999-07-08
AU1690799A (en) 1999-07-19
HUP0001183A3 (en) 2002-12-28
WO1999033841B1 (en) 2001-05-25
CN1261366A (zh) 2000-07-26
WO1999033841A3 (en) 1999-09-02

Similar Documents

Publication Publication Date Title
US6713634B2 (en) Pyrroloazepine derivatives
EP0557526B1 (en) Pyrroloazepine compound
US7057036B2 (en) Pyrrolothiazine and pyrrolothiazepine compounds having serotonin-2 receptor antagonistic and alpha-1-blocking action
JPWO1997020845A1 (ja) ピロロアゼピン誘導体
KR100425953B1 (ko) 티오피란유도체
JPWO1993003032A1 (ja) ピロロアゼピン化合物
US6331623B1 (en) Pyrrolothiazine and pyrrolothiazepine compounds having serotonin-2 receptor antagonistic and alpha-1-blocking action
KR100255131B1 (ko) 피롤로아제핀유도체를함유하는의약
US6211362B1 (en) Pyrroloazepine compounds

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 19990824

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20030321

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20031216

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20050715

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20070516

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20050715

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I